In 2014, the American Cancer Society (ACS) estimates that 233,000 new cases of prostate cancer will be diagnosed in the United States. Most men are managed with either radiation therapies or surgery with recurrence rates as high as 25-40%. No matter how expertly done, these therapies carry significant risk and morbidity to the patient’s health related quality of life with impact on sexual, urinary and bowel function. For this reason, focal or regional treatments for low risk native and recurrent prostate cancer patients are beginning to be adopted. Although questions remain, focal therapies are becoming more attractive to patients who are demanding more options. MR imaging provides the best lesion visualization for both native and recurrent prostate cancer. However, until recently treatment in the MR suite has not been possible. Now MR guided cryoablation, laser ablation and focused ultrasound are possible. We will discuss the use of MR guided cryoablation in treatment of native and recurrent prostate cancer.
Woodrum, D,
Genitourinary Keynote Speaker: Fibroid Expert Topic—MR Guided Focal Cryoablation for Native and Recurrent Prostate Cancer. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL.
http://archive.rsna.org/2014/14044452.html
